- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential...
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P...
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium...
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant...
PALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused...
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment...
BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential...